Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement
Executive Summary
Legal agreement with FDA allowing communication about off-label Vascepa use is not limited by audience, speaker or setting, attorneys say.
You may also be interested in...
FDA Creates Division To Support First Amendment Policy Development, Oversee Advertising Research
Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.
When Expanded Access Also Means Off-Label Use, US FDA May Need New Policy
For now, FDA is using a case-by-case approach for reviewing and approving expanded access applications asking for off-label uses.
Amarin Says REDUCE-IT Results Are Off Limits To Omega-3 Supplement Claims
REDUCE-IT results are limited to Amarin's Vascepa "and cannot be extrapolated to omega-3 products that are materially different based on, for example, composition, dosage, and regulatory status," pharma firm says in complaints against Coromega and Omax. Amarin seeks to stifle the omega-3 supplement firms despite First Amendment argument it made in successful litigation against FDA to make truthful statements about its products even though the information is not approved by the agency.